Sun Pharma gets warning letter from USFDA over Halol unit
Sun Pharma gets warning letter from USFDA over Halol unit

Drug major Sun Pharmaceutical Industries on Saturday said it has received a warning letter from the USFDA over violation of manufacturing norms in its facility at Halol in Gujarat.

Sun Pharma Q2 net profit dips 46% to Rs 1,107 crore
Sun Pharma Q2 net profit dips 46% to Rs 1,107 crore

Drug major Sun Pharmaceutical Industries on Saturday reported 46.02 percent dip in its consolidated net profit at Rs 1,106.66 crore for the second quarter ended September 30, 2015 on account of lower sales, volatile currency movements and supply constraints.

Sun Pharma withdraws suit filed by Ranbaxy against USFDA
Sun Pharma withdraws suit filed by Ranbaxy against USFDA

The lawsuit challenged FDA's revocation of Ranbaxy's tentative approvals for its generic versions of Nexium and Valcyte in the US.

Sun Pharma shareholders approve amalgamation scheme

Sun Pharmaceutical on Friday said court convened meeting of its shareholders has approved the scheme of amalgamation of Sun Pharma Global Inc with itself.

Sun Pharma, AstraZeneca seal distribution deal

Drug majors Sun Pharmaceutical and AstraZeneca Pharma India (AZPIL) on Tuesday said they have entered into a distribution services agreement to distribute AstraZeneca's heart disease treatment drug 'Axcer' in India.

Sun Pharma, not sated by Ranbaxy deal, may spend up to $7 billion on M&A: Bankers

Sun Pharma, which has a market value of nearly $36 billion, is also interested in non-biotech complex generic medicine.

Sun Pharma shares bounce back, up nearly 2% at close

Shares of Sun Pharmaceutical Wednesday recovered nearly 2 percent to close at Rs 967.15 on BSE a day after the stock took a severe beating following Daiichi Sankyo selling its entire 9 percent stake in the company for Rs 20,025 crore.

Shanghvi did not buy Daiichi Sankyo's shares: Sun Pharma

The company was clarifying on speculations that Sanghvi, who holds 9.61 percent stake in Sun Pharma, had bought shares when Daiichi Sankyo exited from the Indian firm.

Daiichi Sankyo exits Sun Pharma; ends 7 years of tumultuous ride in India
Daiichi Sankyo exits Sun Pharma; ends 7 years of tumultuous ride in India

The company, which had forayed into the growing Indian pharmaceutical market by buying a majority stake in Ranbaxy Laboratories in 2008 for Rs 22,000 crore, sold over 21 crore shares in Sun Pharma.

Japan's Daiichi completely exits Sun Pharma

Yesterday, Daiichi Sankyo Company Ltd had announced its decision to sell "the entire or part of its holdings of Sun Pharmaceutical shares..."

Daiichi Sankyo to offload stake in Sun Pharma worth Rs 22,000 cr

Japanese drug maker Daiichi Sankyo Monday said it board has approved selling a part or entire 9 percent holding worth over Rs 22,000 crore in Indian drug major Sun Pharmaceutical.

Ranbaxy stock to stop trading on exchanges from next week

Shares of Ranbaxy Laboratories will stop trading on BSE and NSE with effect from April 6 onwards as the company is merging with Sun Pharmaceutical Industries in a USD 4 billion deal.

Ranbaxy ends last trading day on bright note; surges over 5%

Shares of Ranbaxy Laboratories on Wednesday ended with strong gains on the last day of its trade, as the company is being merged with Sun Pharmaceutical in a USD 4 billion deal.

HC allows merger of Ranbaxy and Sun pharma

The Punjab and Haryana High Court Monday gave its nod to the merger of two Indian pharmaceutical companies - Ranbaxy Laboratories Limited with Sun Pharmaceutical Industries Limited.

Dilip Shanghvi to buy equity worth Rs 1,800 crore in Suzlon

Wind turbine maker Suzlon Energy has signed definitive agreements with Dilip Shanghvi Family and Associates (DSA) for equity investments of Rs 1,800 crore.

Sun Pharma falls 6% on reports of FDA inspection at Halol unit

Sun Pharmaceutical Industries on Thursday slumped as much as 6 percent, heading towards its biggest single day fall since March 16, 2012.

Sun Pharma recalls 200 vials of cancer drug: FDA

Sun Pharmaceutical Industries Ltd is recalling 200 vials of the chemotherapy drug gemcitabine in the United States due to a lack of assurance of sterility, the U.S. Food and Drug Administration said on Thursday.

Ranbaxy Q4 net loss at Rs 73.6 cr

Drug major Ranbaxy Laboratories on Friday posted consolidated net loss of Rs 73.6 crore for the fourth quarter ended March 31, 2014

Crisil reaffirms 'A1+' rating on Ranbaxy's bank facilities

Rating agency Crisil has reaffirmed its 'A1+' rating on bank facilities of Ranbaxy Laboratories post Sun Pharmaceutical Industries's announcement to acquire 100 percent stake in it.

Sebi gets complaints on Ranbaxy share trade before merger deal

Market regulator Sebi has received multiple complaints about alleged irregularities in trading of Ranbaxy shares before the announcement of its multi-billion dollar merger deal with Sun Pharmaceutical.